Advanced cell programming

An extensive cell programming capability

Engineered T cell immunotherapy products show significant efficacy for hematological malignancies

However, realization of the potential of this approach across a broad range of tumor types will require multiple technology solutions to address limitations of the current generation of therapies.

Our technological approach is the development of advanced T-cell engineering components designed to directly address clinical challenges. A focus on our early-stage pipeline incorporates multiple components in a single product.

Latest Abstracts & Publications

See all
Nature Medicine
July 06 2023

Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia

Cancer Immunology Research
June 26 2023

Enhancing CAR T cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors

Activity enhancement
Journal for ImmunoTherapy of Cancer
May 26 2023

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy